Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
VectorY logo — VectorY combines the therapeutic potential of antibodies and...

VectorY

VectorY combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions.

Founded 2020 The Netherlands The Netherlands 114 employees Series A Total: $160.00M Biotechnology

General Information

Company Name VectorY
Founded Year 2020
Location The Netherlands The Netherlands
Founders / Decision Makers
Team member
Employees 114
Industries Biotechnology
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with VectorY. To contact VectorY, visit vectorytx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does VectorY compare?

A PDF of VectorY and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting VectorY soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About VectorY

VectorY is a promising player in the Biotechnology industry, leveraging the therapeutic potential of antibodies and gene therapy to address large disease areas with high unmet medical needs. Founded in August 2020 and based in the Amsterdam Science Park, this fully integrated gene therapy company is making strides in developing innovative treatments, particularly focusing on CNS and muscle disorders.

The company distinguishes itself with its proprietary AAV-based vectorized antibody and gene therapy platform, which is geared towards enhancing therapeutic innovation. Their headway is reinforced by their own manufacturing facilities, capable of delivering suspension-based AAV viral vector manufacturing up to 2000L, ensuring scalability from clinical to commercial supply.

VectorY secured a substantial €129.00M Series A investment on 01 November 2023, backed by notable investors including Insight Partners, BioGeneration Ventures, Forbion, ALS Investment Fund, EQT Life Sciences, and MRL Ventures.

Business keywords: gene therapy, antibody therapy, vectorized antibodies, CNS disorders, somatic disorders, muscle diseases, AAV-based vector technology, therapeutic development, biopharmaceutical manufacturing, suspension-based viral vector manufacturing, GMP facility, innovative therapeutics, R&D

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A €129.00M 6
Insight Partners BioGeneration Ventures Forbion
Insight Partners, BioGeneration Ventures +4
01 Nov 2023
Seed €31.00M 3
BioGeneration Ventures Forbion Eli Lilly
BioGeneration Ventures, Forbion +1
01 Jun 2021

Latest News

View All
Capital meets care: 10 venture capital firms transforming healthcare across Europe — Eu-startups
Capital meets care: 10 venture capital firms transforming healthcare across Europe
Eu-startups Sep 18, 2025

VectorY Alternatives & Competitors

View All Alternatives
VectorY vs
StrideBio, Inc
StrideBio, Inc United States

The next evolution in gene therapy

Acquired
4 employees
Biotechnology, Health Care
Compare VectorY vs StrideBio, Inc
VectorY vs
REGENXBIO
REGENXBIO United States

Seeking to improve lives through the curative potential of gene therapy.

IPO
389 employees
Biopharma, Biotechnology
Compare VectorY vs REGENXBIO
VectorY vs
ProBio
ProBio United States

Manufacturing Life-Changing Therapies

Series C
246 employees
Biopharma, Biotechnology
Also compare with: VectorY vs Abeona Therapeutics Abeona Therapeutics VectorY vs MeiraGTx MeiraGTx View all alternatives

FAQ About VectorY

VectorY combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions.
VectorY was founded in 2020.
VectorY is headquartered in The Netherlands.
VectorY operates in Biotechnology. Its work centres on gene therapy, antibody therapy, vectorized antibodies and CNS disorders.
VectorY has approximately 114 employees.
VectorY has completed 2 funding rounds, raising a total of $160.00M. The latest funding stage is Series A.
Top alternatives and competitors to VectorY include StrideBio, Inc, REGENXBIO, ProBio, Abeona Therapeutics, Coave Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
VectorY and StrideBio, Inc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for VectorY, https://bouncewatch.com/company/vectory, updated 25 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes